PURPOSE Allogeneic hematopoietic cell transplantation (HCT) is the only potentially
curative therapy for myelodysplastic syndromes (MDS), although it is infrequently offered to …

Purpose Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders that are
more common in patients aged≥ 60 years and are incurable with conventional therapies …

Importance Matched sibling donors (MSDs) are preferred for allogeneic hematopoietic cell
transplantation (allo-HCT) in myelodysplastic syndrome even if they are older. However …

Allogeneic hematopoietic stem cell transplantation (SCT) is well accepted as a curative
treatment approach for younger patients with myelodysplastic syndrome (MDS) and has …

Purpose This study was performed to examine the characteristics of transplant activity for
patients with myelodysplastic syndromes (MDS) older than 50 years within the European …

Standard first-line therapy for older patients with high-risk myelodysplastic syndrome (MDS)
includes hypomethylating agents, such as azacitidine (AZA). However, the only approach …

No standard exists for the treatment of myelodysplastic syndrome relapsing after allogeneic
stem cell transplantation. We performed a retrospective registry analysis of outcomes and …

Purpose To compare a reduced-intensity conditioning regimen (RIC) with a myeloablative
conditioning regimen (MAC) before allogeneic transplantation in patients with …

Allogeneic stem cell transplantation is the only known curative therapy for myelodsyplastic
syndromes (MDS). We present the transplant outcomes for 84 adult MDS patients, median …

Allogeneic hematopoietic stem cell transplantation (HSCT) represents the only curative
treatment for patients with myelodysplastic syndrome (MDS), but involves non‐negligible …